Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.
The burden of severe COVID-19 tends to be high in people with lung cancer, with patient-specific factors having the greatest impact on severity, indicates a chart review from a single center.
TRK inhibitor therapy has a “unique” profile of adverse events, suggests a review of lung cancer and other oncology patients attending the Memorial Sloan Kettering Cancer Center in New York, USA.
Patients with extensive-stage small-cell lung cancer derive a progression-free survival benefit from first-line treatment with pembrolizumab plus chemotherapy, show phase 3 KEYNOTE-604 trial findings.
Treatment with PD-1 inhibitors does not appear to worsen the severity of SARS-CoV-2 infection in patients with lung cancer, suggests a single-center analysis.
Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.